27622027|t|CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients
27622027|a|CD169 was first identified on macrophages (Mϕ) and linked to antigen presentation. Here, we showed CD169 expression on some CD8(+) T lymphocytes in regional lymph nodes (LNs) and investigated the function and clinical relevance of CD169(+)CD8(+) T cells in tumor-draining LNs of colorectal cancer (CRC) patients. Fresh tumor-draining LN tissues from 39 randomly enrolled patients were assessed by flow cytometry for activation and differentiation of CD169(+)CD8(+) T cells and T cell-mediated killing of tumor cells. In total, 114 tumor-draining LN paraffin sections from CRC patients were analyzed by multiple-color immunofluorescence for CD169(+)CD8(+) T cell distribution and clinical values. The prognostic significance of CD169(+)CD8(+) T cells was evaluated by Kaplan-Meier analysis. A fraction of CD8(+) T cells in regional LNs, but not peripheral blood, tonsils, or tumors, expressed surface CD169. In situ detection of draining LNs revealed preferential localization of CD169(+)CD8(+) T cells to subcapsular sinus and interfollicular regions, closely associated with CD169(+) Mϕ. CD169(+)CD8(+) T cell ratios were significantly lower in peri-tumor LNs than distant-tumor LNs. CD169(+)CD8(+) T cells predominantly expressed activation markers (CD69, HLA-DR, PD-1) with slightly lower CD45RA and CD62L levels. They produced high granzyme B, perforin, TNF-α, and IFNγ levels, and promoted tumor-killing efficiency ex vitro. Moreover, CD169(+)CD8(+) T cells infiltrating tumor-draining LNs decreased with disease progression and were strongly associated with CRC patient survival. We identified novel activated / cytolytic CD169(+)CD8(+) T cells selectively present in regional LNs, potentially serving as a powerful prognostic factor and indicator for selecting patients for immunotherapy.
27622027	0	5	CD169	T103	UMLS:C1608815
27622027	6	16	identifies	T033	UMLS:C0243095
27622027	20	29	activated	T017	UMLS:C1515879
27622027	30	43	CD8(+) T cell	T017	UMLS:C0242629
27622027	44	50	subset	T170	UMLS:C0079720
27622027	54	74	regional lymph nodes	T017	UMLS:C1179441
27622027	99	108	prognosis	T058	UMLS:C0033325
27622027	112	129	colorectal cancer	T038	UMLS:C1527249
27622027	139	144	CD169	T103	UMLS:C1608815
27622027	169	180	macrophages	T017	UMLS:C0024432
27622027	182	184	Mϕ	T017	UMLS:C0024432
27622027	200	220	antigen presentation	T038	UMLS:C0206431
27622027	238	254	CD169 expression	T038	UMLS:C0017262
27622027	263	283	CD8(+) T lymphocytes	T017	UMLS:C0242629
27622027	287	307	regional lymph nodes	T017	UMLS:C1179441
27622027	309	312	LNs	T017	UMLS:C1179441
27622027	335	343	function	T038	UMLS:C0031843
27622027	348	366	clinical relevance	T033	UMLS:C0243095
27622027	370	392	CD169(+)CD8(+) T cells	T017	UMLS:C0039194
27622027	396	414	tumor-draining LNs	T017	UMLS:C0024204
27622027	418	435	colorectal cancer	T038	UMLS:C1527249
27622027	437	440	CRC	T038	UMLS:C1527249
27622027	452	483	Fresh tumor-draining LN tissues	T017	UMLS:C0440747
27622027	536	550	flow cytometry	T058	UMLS:C0016263
27622027	570	585	differentiation	T038	UMLS:C0007589
27622027	589	611	CD169(+)CD8(+) T cells	T017	UMLS:C0039194
27622027	616	654	T cell-mediated killing of tumor cells	T038	UMLS:C1523368
27622027	670	687	tumor-draining LN	T017	UMLS:C0024204
27622027	711	714	CRC	T038	UMLS:C1527249
27622027	741	774	multiple-color immunofluorescence	T058	UMLS:C0016318
27622027	779	800	CD169(+)CD8(+) T cell	T017	UMLS:C0039194
27622027	839	849	prognostic	T170	UMLS:C0220901
27622027	866	888	CD169(+)CD8(+) T cells	T017	UMLS:C0039194
27622027	893	902	evaluated	T058	UMLS:C0220825
27622027	943	957	CD8(+) T cells	T017	UMLS:C0242629
27622027	961	973	regional LNs	T017	UMLS:C1179441
27622027	983	999	peripheral blood	T031	UMLS:C0229664
27622027	1001	1008	tonsils	T017	UMLS:C0836921
27622027	1013	1019	tumors	T038	UMLS:C0027651
27622027	1021	1044	expressed surface CD169	T103	UMLS:C1608815
27622027	1046	1053	In situ	T082	UMLS:C0444498
27622027	1054	1063	detection	T058	UMLS:C1511790
27622027	1067	1079	draining LNs	T017	UMLS:C0024204
27622027	1118	1140	CD169(+)CD8(+) T cells	T017	UMLS:C0039194
27622027	1144	1161	subcapsular sinus	T017	UMLS:C1518052
27622027	1166	1189	interfollicular regions	T082	UMLS:C1512836
27622027	1215	1226	CD169(+) Mϕ	T017	UMLS:C0024432
27622027	1228	1249	CD169(+)CD8(+) T cell	T017	UMLS:C0039194
27622027	1296	1299	LNs	T017	UMLS:C0024204
27622027	1319	1322	LNs	T017	UMLS:C0024204
27622027	1324	1346	CD169(+)CD8(+) T cells	T017	UMLS:C0039194
27622027	1371	1389	activation markers	T201	UMLS:C0005516
27622027	1391	1395	CD69	T103	UMLS:C0108800
27622027	1397	1403	HLA-DR	T103	UMLS:C0019764
27622027	1405	1409	PD-1	T103	UMLS:C0135710
27622027	1431	1437	CD45RA	T103	UMLS:C0108789
27622027	1442	1447	CD62L	T103	UMLS:C0125090
27622027	1475	1485	granzyme B	T103	UMLS:C0061878
27622027	1487	1495	perforin	T103	UMLS:C0070410
27622027	1497	1502	TNF-α	T103	UMLS:C1456820
27622027	1508	1512	IFNγ	T103	UMLS:C3539881
27622027	1534	1558	tumor-killing efficiency	T058	UMLS:C1446301
27622027	1579	1601	CD169(+)CD8(+) T cells	T017	UMLS:C0039194
27622027	1602	1614	infiltrating	T038	UMLS:C0332448
27622027	1615	1633	tumor-draining LNs	T017	UMLS:C0024204
27622027	1649	1668	disease progression	T038	UMLS:C0242656
27622027	1703	1706	CRC	T038	UMLS:C1527249
27622027	1757	1789	cytolytic CD169(+)CD8(+) T cells	T017	UMLS:C0039195
27622027	1813	1825	regional LNs	T017	UMLS:C1179441
27622027	1861	1878	prognostic factor	T201	UMLS:C1514474
27622027	1920	1933	immunotherapy	T058	UMLS:C0021083